Page last updated: 2024-09-03

4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and bd 1063

4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol has been researched along with bd 1063 in 1 studies

Compound Research Comparison

Studies
(4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol)
Trials
(4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol)
Recent Studies (post-2010)
(4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol)
Studies
(bd 1063)
Trials
(bd 1063)
Recent Studies (post-2010) (bd 1063)
70129806

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Amata, E; Artacho-Cordón, A; Barbaraci, C; Cobos, EJ; Dichiara, M; Gómez-Guzmán, M; González-Cano, R; Marrazzo, A; Pasquinucci, L; Rodríguez-Gómez, I; Santos-Caballero, M; Turnaturi, R1

Other Studies

1 other study(ies) available for 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and bd 1063

ArticleYear
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation.
    European journal of medicinal chemistry, 2022, Feb-15, Volume: 230

    Topics: Animals; Guinea Pigs; Hydrogen; Hydrogen Sulfide; Ligands; Male; Morpholines; Pain; Piperazines; Rats, Sprague-Dawley; Receptors, sigma; Sigma-1 Receptor

2022